Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS - Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $469.76 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Hims & Hers Health Trading Down 3.6 %

Shares of NYSE:HIMS traded down $2.46 during trading on Thursday, hitting $66.28. 30,711,275 shares of the company's stock were exchanged, compared to its average volume of 15,817,041. Hims & Hers Health has a 1-year low of $9.22 and a 1-year high of $72.98. The firm has a 50-day moving average price of $33.94 and a two-hundred day moving average price of $25.19. The firm has a market cap of $14.48 billion, a P/E ratio of 150.64 and a beta of 1.35.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a research note on Monday, January 6th. TD Cowen reissued a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Citigroup lowered shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price objective for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, January 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and an average price target of $28.53.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Melissa Baird sold 67,687 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $44.71, for a total transaction of $3,026,285.77. Following the transaction, the chief operating officer now owns 706,872 shares in the company, valued at approximately $31,604,247.12. The trade was a 8.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,052,332 shares of company stock valued at $32,620,497 over the last 90 days. 17.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.